All In Biotech

Drug Trial Radar · NCT02849457

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSC

Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

Dec 2016

Primary completion

Apr 26, 2023

Study completion May 5, 2023

Sponsor

Lead sponsor
Martina BebinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Jul 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 1 day, up to 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study design is a Phase IIb prospective multi-center, randomized, placebo-controlled, double-blind clinical trial. The goal will be to enroll 80 infants with Tuberous Sclerosis Complex who are less than 6 months of age prior to the onset of their first seizure

Conditions

  • Tuberous Sclerosis Complex

Interventions

  • Early VigabatrinDrug

    Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.

  • Delayed Vigabatrin (Placebo)Drug

    Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cognitive Assessment Scores and Developmental ImpactTime frame: 24 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California, Los Angeles

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Boston Children's Hospital

    Boston, Massachusetts

  • Beaumont Children's Hospital

    Royal Oak, Michigan

  • Minnesota Epilepsy Group, PA

    Saint Paul, Minnesota

  • Washington University in St. Louis

    St Louis, Missouri

  • Duke University

    Durham, North Carolina

  • Cincinnati's Children Hospital Medical Center

    Cincinnati, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.